Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2016-03-10 Director's Dealing
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2016-03-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-02-17 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-02-17 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure of a Chief Operating Officer, including the terms of his separation agreement and compensation arrangements. This corresponds to announcements about changes in the company's board of directors or senior management. There is no financial data or report attached, nor is it an earnings release or annual report. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3624 characters, which is consistent with a typical 8-K filing for management changes. Confidence is high due to the clear mention of departure and employment separation agreement of a senior officer.
2016-02-08 English
FORM 8-K
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a legal proceeding initiated by the company, Atossa Genetics Inc., including details about a complaint filed in a U.S. District Court. There are no financial statements or detailed financial data presented. The document is primarily an announcement of a legal event. According to the filing definitions, updates on significant lawsuits or regulatory actions fall under Legal Proceedings Report (LTR). The document is not an Annual Report, Earnings Release, or any other financial report type. It is also not a report publication announcement or a certification. Therefore, the appropriate classification is Legal Proceedings Report (LTR). The confidence in this classification is high given the clear description of a legal complaint and the nature of the Form 8-K filing.
2016-01-29 English
AMENDMENT NO. 1
Major Shareholding Notification
2016-01-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.